Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.

Authors

K Reich
M Gooderham
A Bewley
L Green, George Washington University
J Soung
R Petric
J Marcsisin
J Cirulli
R Chen
V Piguet

Document Type

Journal Article

Publication Date

3-1-2018

Journal

Journal of the European Academy of Dermatology and Venereology : JEADV

Volume

32

Issue

3

DOI

10.1111/jdv.14738

Keywords

Adult; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration Schedule; Etanercept; Female; Humans; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Placebos; Psoriasis; Quality of Life; Severity of Illness Index; Thalidomide

APA Citation

Reich, K., Gooderham, M., Bewley, A., Green, L., Soung, J., Petric, R., Marcsisin, J., Cirulli, J., Chen, R., & Piguet, V. (2018). Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study.. Journal of the European Academy of Dermatology and Venereology : JEADV, 32 (3). http://dx.doi.org/10.1111/jdv.14738

Peer Reviewed

1